A Phase 3 interventional study of Brivaracetam (BRV) in Epilepsy, sponsored by UCB Pharma SA. Completed at 56 sites in 12 countries. Open to participants aged 28 Days to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 9th largest by enrollment, is one of 4 that started in 2011, is one of 21 in phase 3, and was the 17th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 28 Days to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2011.
This study's enrollment of 257 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma SA, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma SA is the lead sponsor of 28 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 32nd largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 73rd registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.
This is a Phase 3, open-label, single-arm, multicenter, long-term study to evaluate the safety and efficacy of brivaracetam (BRV) in children with epilepsy.
This study was initially designed for pediatric subjects who had completed a previous BRV study.
With protocol amendment 4, enrollment for "directly enrolled" subjects was modified from 'up to' an additional 100 subjects to "at least" 100 subjects, keeping the planned total enrollment of approximately 600 subjects to allow flexibility in the number of patients reaching 1 year of exposure.
With protocol amendment 5, entry criteria for subjects coming for other pediatric core studies in development were included. Additional clarity was provided for subjects enrolled in N01266 that temporary roll over to one of those studies and resume participation in N01266.
With protocol amendment 6, central EEG reading and entry visit EEG were removed. Some clarifications on study assessments (questionnaires, EEGs) was provided and inclusion criteria were aligned from an earlier local amendment.
With protocol amendment 7, the pregnancy section was updated to clarify that Pregnancy Report and Outcome Form has to be completed in all pregnancies.
With protocol amendment 8, re-categorization of study variables in compliance with reporting registries was performed. Modifications due to COVID19 pandemic were implemented and clarification provided that participants may transition to another BRV study.
The primary objective is to evaluate the long-term safety and tolerability of BRV. The secondary objective is to assess the efficacy of BRV during long-term exposure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Subjects:
OR if women of childbearing potential, and sexually active only if:
Long Term Follow-up Subjects:
- Male or female subjects having participated in a core study with a confirmed diagnosis of epilepsy and for whom a reasonable benefit from long-term administration of BRV is expected
Directly Enrolled Subjects:
Exclusion Criteria:
All Subjects:
Long Term Follow-up Subjects:
Directly Enrolled Subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Brivaracetam (BRV)
The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
TEAEs are defined as AEs that had onset on or after the day of first BRV dose.
Time frame: From Baseline to end of study (up to 10 years)
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
TEAEs are defined as AEs that had onset on or after the day of first BRV dose. A SAE was defined as an event that met 1 or more of the below criteria: a) Death, b) Life-threatening, (Life-threatening did not include a reaction that might have caused death had it occurred in a more severe form.) c) Significant or persistent disability/incapacity, d) Congenital anomaly/birth defect (including that occurring in a fetus), e) Important medical event that, based upon appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious, (Important medical events may have included allergic bronchospasm requiring intensive treatment in an emergency room \[ER\] or at home) f) Initial inpatient hospitalization or prolongation of hospitalization. (A participant admitted to a hospital, even if released on the same day, met the criteria for the initial inpatient hospitalization).
Time frame: From Baseline to end of study (up to 10 years)
Absolute Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on Daily Record Card [DRC])
Absolute change in seizure frequency per 28 days based on the daily record card (DRC) data, is calculated as baseline seizure frequency per 28 days minus post-Baseline seizure frequency per 28 days. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only. Here in the study FAS indicates Full Analysis Set, EEG indicates electroencephalogram, OM indicates Outcome measure
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Percent Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on DRC Data)
Percent change is calculated as absolute change in seizure frequency per 28 days divided by baseline seizure frequency per 28 Days multiplied to 100. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only.
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
50% Responder Rate for Participants ≥2 Years of Age for Total Seizures (All Types) (Based on DRC Data)
A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants or during this study for DE participants. This OM was analyzed in participants ≥2 years (per DRC data) only.
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Absolute Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)
Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants \<2 years (per EEG data) only.
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Percent Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)
Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants \<2 years (per EEG data) only.
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
50% Responder Rate for Participants <2 Years of Age for Total Seizures (All Types) (Based on EEG Data)
A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants. This OM was analyzed in participants \<2 years (per EEG data) only.
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Absolute Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)
Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Percent Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)
Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
50% Responder Rate for Total Seizures (All Types) in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)
A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants.
Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
The study started to enroll participants in August 2011 and concluded in February 2022.
| Milestone | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years |
|---|---|---|---|---|
| Started | 36 | 15 | 141 | 65 |
| Directly enrolled (de) participants | 0 | 0 | 85 | 35 |
| Long-term follow-up (ltfu) participants | 36 | 15 | 56 | 30 |
| Completed | 18 | 4 | 65 | 37 |
| Not completed | 18 | 11 | 76 | 28 |
| Withdrew: Adverse event | 4 | 5 | 16 | 7 |
| Withdrew: Lack of efficacy | 4 | 4 | 23 | 8 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 5 | 3 |
| Withdrew: Withdrawal by subject | 4 | 1 | 18 | 6 |
| Withdrew: Non compliance | 1 | 0 | 1 | 0 |
| Withdrew: Lack of compliance | 1 | 0 | 0 | 0 |
| Withdrew: End of treatment epilepsy | 1 | 0 | 0 | 0 |
| Withdrew: No seizures | 1 | 0 | 0 | 0 |
| Withdrew: Lack of reliability from the subject's caregiver | 1 | 0 | 0 | 0 |
| Withdrew: Cure | 1 | 0 | 0 | 0 |
| Withdrew: Patient was moving | 0 | 1 | 0 | 0 |
| Withdrew: Seizures resolved | 0 | 0 | 1 | 0 |
| Withdrew: Patient became seizure-free after surgery | 0 | 0 | 1 | 0 |
| Withdrew: 5 year without seizures. treatment is finish | 0 | 0 | 1 | 0 |
| Withdrew: Patient cured from epilepsy | 0 | 0 | 1 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor recommended discontinuation | 0 | 0 | 0 | 1 |
| Withdrew: Parents went abroad with the patient | 0 | 0 | 1 | 0 |
| Withdrew: Brv discontinued as no seizures during 2 years | 0 | 0 | 1 | 0 |
| Withdrew: Brv administration dropout | 0 | 0 | 1 | 0 |
| Withdrew: Dropout | 0 | 0 | 3 | 1 |
| Withdrew: Unreliable subject | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
TEAEs are defined as AEs that had onset on or after the day of first BRV dose.
| percentage of participants | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years |
|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 94.4 | 93.3 | 93.6 | 92.3 |
TEAEs are defined as AEs that had onset on or after the day of first BRV dose. A SAE was defined as an event that met 1 or more of the below criteria: a) Death, b) Life-threatening, (Life-threatening did not include a reaction that might have caused death had it occurred in a more severe form.) c) Significant or persistent disability/incapacity, d) Congenital anomaly/birth defect (including that occurring in a fetus), e) Important medical event that, based upon appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious, (Important medical events may have included allergic bronchospasm requiring intensive treatment in an emergency room \[ER\] or at home) f) Initial inpatient hospitalization or prolongation of hospitalization. (A participant admitted to a hospital, even if released on the same day, met the criteria for the initial inpatient hospitalization).
| percentage of participants | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years |
|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study | 38.9 | 53.3 | 29.8 | 29.2 |
Absolute change in seizure frequency per 28 days based on the daily record card (DRC) data, is calculated as baseline seizure frequency per 28 days minus post-Baseline seizure frequency per 28 days. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only. Here in the study FAS indicates Full Analysis Set, EEG indicates electroencephalogram, OM indicates Outcome measure
| seizure frequency per 28-days | Brivaracetam (BRV): Participants ≥ 2 Years to <17 Years |
|---|---|
| Absolute Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on Daily Record Card [DRC]) | -37.48 ± 628.34 |
Percent change is calculated as absolute change in seizure frequency per 28 days divided by baseline seizure frequency per 28 Days multiplied to 100. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only.
| percent change | Brivaracetam (BRV): Participants ≥ 2 Years to <17 Years |
|---|---|
| Percent Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on DRC Data) | 26.57 ± 123.06 |
A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants or during this study for DE participants. This OM was analyzed in participants ≥2 years (per DRC data) only.
| percentage of participants | Brivaracetam (BRV): Participants ≥2 Years to <17 Years |
|---|---|
| 50% Responder Rate for Participants ≥2 Years of Age for Total Seizures (All Types) (Based on DRC Data) | 50.9 |
Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants \<2 years (per EEG data) only.
| seizures per day | Brivaracetam (BRV): Participants ≥1 Month to <2 Years |
|---|---|
| Absolute Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data) | 2.56 ± 4.44 |
Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants \<2 years (per EEG data) only.
| percent change | Brivaracetam (BRV): Participants ≥1 Month to <2 Years |
|---|---|
| Percent Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data) | 98.72 ± 2.22 |
A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants. This OM was analyzed in participants \<2 years (per EEG data) only.
| percentage of participants | Brivaracetam (BRV): Participants ≥1 Month to <2 Years |
|---|---|
| 50% Responder Rate for Participants <2 Years of Age for Total Seizures (All Types) (Based on EEG Data) | 75.0 |
Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.
No measurements were reported for this outcome.
Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.
No measurements were reported for this outcome.
A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants.
No measurements were reported for this outcome.
Collected over From Baseline to end of Study (up to 10 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Age Cohort: ≥1 Month to <2 Years | 2/36 (5.6%) | 14/36 (38.9%) | 30/36 (83.3%) |
| Age Cohort: ≥2 to <4 Years | 2/15 (13.3%) | 8/15 (53.3%) | 13/15 (86.7%) |
| Age Cohort: ≥4 to <12 Years | 2/141 (1.4%) | 42/141 (29.8%) | 120/141 (85.1%) |
| Age Cohort: ≥12 to <17 Years | 1/65 (1.5%) | 19/65 (29.2%) | 51/65 (78.5%) |
| Event | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years |
|---|---|---|---|---|
| SeizureNervous system disorders | 1/36 | 1/15 | 12/141 | 2/65 |
| PneumoniaInfections and infestations | 3/36 | 0/15 | 4/141 | 1/65 |
| Spina bifidaCongenital, familial and genetic disorders | 0/36 | 1/15 | 0/141 | 0/65 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/36 | 1/15 | 0/141 | 0/65 |
| StomatitisGastrointestinal disorders | 0/36 | 1/15 | 0/141 | 0/65 |
| ToothacheGastrointestinal disorders | 0/36 | 1/15 | 0/141 | 0/65 |
| PyrexiaGeneral disorders | 2/36 | 1/15 | 3/141 | 0/65 |
| Respiratory tract infectionInfections and infestations | 0/36 | 1/15 | 0/141 | 0/65 |
| Generalised tonic-clonic seizureNervous system disorders | 1/36 | 1/15 | 2/141 | 1/65 |
| Simple partial seizuresNervous system disorders | 0/36 | 1/15 | 1/141 | 0/65 |
| Event | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 15/36 | 4/15 | 37/141 | 7/65 |
| VomitingGastrointestinal disorders | 11/36 | 5/15 | 34/141 | 4/65 |
| Upper respiratory tract infectionInfections and infestations | 10/36 | 5/15 | 23/141 | 8/65 |
| NasopharyngitisInfections and infestations | 11/36 | 4/15 | 44/141 | 16/65 |
| PharyngitisInfections and infestations | 10/36 | 2/15 | 39/141 | 8/65 |
| PneumoniaInfections and infestations | 4/36 | 4/15 | 9/141 | 0/65 |
| HeadacheNervous system disorders | 0/36 | 1/15 | 21/141 | 16/65 |
| GastroenteritisInfections and infestations | 8/36 | 0/15 | 16/141 | 5/65 |
| BronchitisInfections and infestations | 7/36 | 3/15 | 16/141 | 1/65 |
| Urinary tract infectionInfections and infestations | 2/36 | 3/15 | 6/141 | 4/65 |
Baseline characteristics refers to the Enrolled Set (ES) which included all study participants with epilepsy who gave informed consent, or for whom informed consent was given by parent(s)/legal representative(s).
| Age, Categorical(Participants) | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years | Total |
|---|---|---|---|---|---|
| <=18 years | 36 | 15 | 141 | 65 | 257 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years | Total |
|---|---|---|---|---|---|
| Mean | 1.122 ± 0.504 | 2.761 ± 0.582 | 7.699 ± 2.394 | 13.824 ± 1.274 | 8.039 ± 4.529 |
| Sex: Female, Male(Participants) | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years | Total |
|---|---|---|---|---|---|
| Female | 19 | 5 | 62 | 30 | 116 |
| Male | 17 | 10 | 79 | 35 | 141 |
| Race/Ethnicity, Customized(Participants) | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years | Total |
|---|---|---|---|---|---|
| American Indian/ Alaskan native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Black | 0 | 0 | 2 | 2 | 4 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 28 | 14 | 107 | 48 | 197 |
| Other/Mixed | 8 | 1 | 32 | 15 | 56 |
| Race/Ethnicity, Customized(Participants) | Age Cohort: ≥1 Month to <2 Years | Age Cohort: ≥2 to <4 Years | Age Cohort: ≥4 to <12 Years | Age Cohort: ≥12 to <17 Years | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 1 | 38 | 19 | 69 |
| Not Hispanic or Latino | 24 | 14 | 103 | 46 | 187 |
| Missing | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2011 to primary completion in Feb 2022, 126 months.
Results were first posted in Aug 2022, 6 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 126 months is above that.
Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam